• BioMatch listed on MOSIP marketplace • Stronger position in government biometrics • Short Q&A with CEO Joakim Nydemark Precise Biometrics ...
• Cautious market climate hampers sales growth • Positive adjusted EBITDA and cash flow • We keep our fair value of SEK 4.
* CEO Joakim Nydemark comments in a video interview * Four strategic reason for the proposed deal * Awaiting the outcome, we keep our fair v...
* Lower sales than estimated in Q4 * The CEO is optimistic for 2026 after a difficult 2025 * Adjustments lead to a lower fair value of SEK 4...
Analytikerna rättar namnet på Precise Biometrics vd som är Joakim Nydemark.
Vd Joakim Samuelsson diskuterar bokslutsrapporten, händelser under året, affärsmodellen, samt möjligheter under 2026 med Västra Hamnens anal...
CEO Joakim Nydemark discusses the year-end report and the events of the past year, business model, opportunities and prospects for 2026 with...
Redeye updates its estimates following the Q3 2024 report from Precise Biometrics.
Redeye provides an initial take on the Q3 2024 report from Precise Biometrics, which is to be considered as very strong.
Redeye provides a research update following the Q2 2024 report from Precise Biometrics.
Redeye gives its initial comments on the Q2 2024 report from Precise Biometrics.
Redye provides a research update following the Q1 2024 report from Precise Biometrics.
Redeye gives its initial comments on the Q1 2024 report from Precise Biometrics, which came in above our expections.
Redeye initiates coverage of Precise Biometrics, a global leader in the fingerprint algorithms space.
Seemingly leaving the trough behind '24e-'25e sales up 2% '24e EV/EBITDA of 5x No surprises - report in line with expectations Q4'23 was br...
Sales SEK 20.3m, +6% vs. ABGSCe SEK 19.1m EBITDA SEK 0.
Moderating growth rebound expectations for Algo '23e-'25e sales down 7-1% '24e EV/EBITDA of 7x What to expect in Q4'23e Q4 smartphone shipm...
Algo could potentially start to rebound in the coming quarters '23e-'25e sales down 9-15% '24e EV/EBITDA of 6x Likely found trough in Algo ...
Sales SEK 17.7m, -13% vs. ABGSCe SEK 20.5m EBITDA SEK -1.
Algo likely to start recovery by the end of '23e '23e-'25e sales down 12-6% '23e-'24e EV/EBITDA of 30-5x Q2'23 in brief Q2'23 came in somewh...
Sales SEK 17.9m, -13% vs. ABGSCe SEK 20.5m EBITDA SEK -0.
We lower '23e-'25e sales by 5-8%Algo rebound as early as H2'23'23e-'24e EV/EBITDA of 27x-5x What to expect in Q2'23 Q2 smartphone shipment d...
Mellan den 15 och 29 maj genomförde Precise Biometrics en företrädesemission, vilken var fullt säkerställd genom garanti- och teckningsförbi...
Teckningsperioden för Precise Biometrics företrädesemission påbörjas idag och pågår till 29 maj.
Analyst Group har idag publicerat en analysartikel avseende Precise Biometrics.
H2'23e Algo recovery increasingly likely '23e-'25e sales down 2-5% '23e-'24e EV/EBITDA of 19-9x Q1'23 in brief Q1'23 came in slightly below...
Sales SEK 19.2m, -7% vs. ABGSCe SEK 20.6m EBITDA SEK -0.
We lower '23e-'25e sales by 8-10% Algo to rebound no earlier than H2'23e Rights issue implies '23e EV/sales of ~0.
Fully secured SEK ~50m rights issue Enables expansion plans Implies post-money valuation of SEK ~125m upon full subscription Terms of the r...
Q4 in brief The fourth quarter came in slightly below what we had expected, as Algo royalties were depressed due to overstocked OEMs.
Sales SEK 19.3m, -16% vs. ABGSCe SEK 22.8m EBITDA SEK -2.
2022e sales cut by 4% Q4 global smartphone shipments -17% y-o-y Announced commercial activities in Q4 strengthen LT outlook Q4'22 estimates...
Sales and EBITDA below ABGSCe in Q3 Digital Identity up-and-coming, Algo hit by macro Share trades at ’23e-’24e EV/sales of 2.
Sales SEK 18.8m, -35% vs. ABGSCe SEK 28.9m EBITDA SEK -1.
Q3 report due Friday, 11 November We reduce ’23e-’24e sales by 3-1% Balance sheet set for growth after share issues Q3’22 expectations We d...
Sales and EBITDA below ABGSCe in Q2 Raises up to SEK 83m in a rights issue Share trades at 3.
Sales and EBITDA beat in Q1 New contracts agreed and we expect more going forward Trades at 3.
Sales +39% y-o-y, +12% vs. ABGSCe EBITDA SEK 4.0m +44% vs.
Q1 revenues of SEK 19m for y-o-y growth of -20.9% Precise Biometrics’ Q2’21 report was below our estimates in terms of revenues due to the g...
